SLC12A2 and glioma: In this study, using two different glioma cell lines (GL26 and SB28-GFP), we further investigated the efficacy of a new BMT-derivative NKCC1 inhibitor STS66 along with well-established NKCC1 inhibitor BMT on regulating glioma NKCC1 activity, K+ influx, and cell growth in response to TMZ.